13534-76-4

Usage

Uses

Used in Pharmaceutical Industry:
6-Phenyl-2-pyrazinecarboxylic acid is used as a key intermediate in the synthesis of biologically active compounds. Its unique structure allows for the development of antiviral and antibacterial agents, making it a valuable component in the creation of new medications to combat various diseases.
Used in Organic Electronics:
6-Phenyl-2-pyrazinecarboxylic acid is utilized as a building block for functional materials in the field of organic electronics. Its properties make it suitable for the development of advanced electronic devices and components, contributing to the advancement of technology in this sector.
Used in Neurological Disorder Treatment:
6-Phenyl-2-pyrazinecarboxylic acid has been studied for its potential role in the treatment of neurological disorders. Its unique chemical properties may offer new avenues for therapeutic intervention, providing hope for patients suffering from such conditions.

Upstream product

• 1074-12-0 phenylglyoxal hydrate 
• 54897-59-5 2,3-diaminopropanoic acid hydrochloride 
• 13534-79-7 methyl 6-phenylpyrazine-2-carboxylate 
• 41270-62-6 2-chloro-6-phenylpyrazine 
• 98-80-6 phenylboronic acid 
• 1186-65-8 hydrobromide salt of D,L-1,2-diaminopropionic acid 

Downstream Products

• 91516-58-4 chloromethyl 6-phenylpyrazin-2-yl ketone 
• 91516-65-3 4-(6'-phenylpyrazin-2'-yl)thiazole-2-thiol 
• 91516-62-0 N,N-dimethyl-2-<4'-(6-phenylpyrazin-2-yl)thiazol-2'-ylthio>ethylamine 
• 91516-59-5 2-(2'-methylthiothiazol-4'-yl)-6-phenylpyrazine 

Relevant academic research and scientific papers

INHIBITORS OF THE WNT SIGNALLING PATHWAYS

The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative disorder, as a sole agent or in combination with other active ingredients.

CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS

The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof, as further described herein. Also provided are formulations comprising compounds of formula I, and a method to use such compounds for treating a disease or condition mediated by Provirus Integration of Maloney Maloney Kinase (PIM Kinase), GSK3, PKC, KDR, PDGFRa, FGFR3, FLT3, or cABL.

TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.

Proteasome inhibitors and methods of using the same

The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly or indirectly with proteasome activity.